Does TORIPALIMAB Cause Reactive capillary endothelial proliferation? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Reactive capillary endothelial proliferation have been filed in association with TORIPALIMAB (LOQTORZI). This represents 0.5% of all adverse event reports for TORIPALIMAB.
6
Reports of Reactive capillary endothelial proliferation with TORIPALIMAB
0.5%
of all TORIPALIMAB reports
1
Deaths
0
Hospitalizations
How Dangerous Is Reactive capillary endothelial proliferation From TORIPALIMAB?
Of the 6 reports, 1 (16.7%) resulted in death.
Is Reactive capillary endothelial proliferation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TORIPALIMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TORIPALIMAB Cause?
Myelosuppression (590)
Off label use (276)
White blood cell count decreased (144)
Anaemia (67)
Hypothyroidism (67)
Neutrophil count decreased (67)
Nausea (60)
Rash (59)
Vomiting (58)
Platelet count decreased (53)
What Other Drugs Cause Reactive capillary endothelial proliferation?
CAMRELIZUMAB (41)
CAPECITABINE (19)
CISPLATIN (19)
DOCETAXEL\DOCETAXEL ANHYDROUS (17)
OXALIPLATIN (11)
ATEZOLIZUMAB (10)
BEVACIZUMAB (10)
PEMBROLIZUMAB (7)
SINTILIMAB (7)
LENVATINIB (5)
Which TORIPALIMAB Alternatives Have Lower Reactive capillary endothelial proliferation Risk?
TORIPALIMAB vs TORSEMIDE
TORIPALIMAB vs TOVIAZ
TORIPALIMAB vs TOVORAFENIB
TORIPALIMAB vs TOZINAMERAN
TORIPALIMAB vs TRABECTEDIN